por Lee Nelson
, Contributing Reporter | August 05, 2016
Men weighing options after a diagnosis of aggressive prostate cancer may be comforted to know outcomes from surgery and high-dose radiation have been found to be equally effective.
“Doctors and health care providers can counsel patients that they have two equivalent treatment options available in terms of survival,” Amar U. Kishan, chief resident for the Department of Radiation Oncology at UCLA, told HCB News.
The research also showed that a particular form of radiotherapy, consisting of external radiation followed by brachytherapy — radiation in which a radioactive source is put directly into the tumor – may give patients the best chance that the cancer won’t spread to other parts of their body.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
His researchers analyzed 487 patients with aggressive prostate cancer between 2000 and 2013 at UCLA and two cancer centers, but Kishan described the age gap between those receiving surgery and those receiving the two different forms of radiation as "statistically significant."
The average age of patients in the research receiving surgery was about 62 years old, versus 69 for patients receiving extremely high-dose radiation and 70 for patients receiving high-dose radiation.
He added that this is another important point to consider when comparing overall survival between different treatment types – generally, patients getting surgery are younger and healthier (i.e., “fit” for surgery), while the radiation groups will include patients who were not candidates for surgery due to age or general health.
“We were able to adjust for age in our conclusions. We didn’t specifically look at ethnicity, which is something we will try to address in future studies,” he explained.
In the study, the percentage of patients dying from aggressive prostate cancer at 10 years was 21.5 percent for surgery, 19.5 percent for high-dose radiation, and 12% for extremely high-dose radiation. The chances of developing metastatic disease (generally requiring chemotherapy) at 10 years was 38.5 percent for surgery, 33.3 percent for high-dose radiation, and 10.2 percent for extremely high-dose radiation.
“We are in the process of expanding our analysis to include patients from several other centers, and particularly looking to expand the number of patients we have who received extremely high-dose radiation,” he said. “This follow-up project will include more patients as well as information about toxicity, as available.”